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Summary: Drug development follows a very specific path, from 
preclinical safety and quality ascertainment to clinical development 
to market authorization and postmarketing surveillance. The whole 
process is geared to the pharmaceutical industry, which indeed has 
all the know-how and experience to bring a drug to market, espe-
cially when it is also the originator of the future drug. When the 
product is derived from academic research, can academia initiate 
drug development, and at what stages? This will depend on the 
availability of the appropriate resources in the academic and/or 
private sectors, and the funding for these. Preclinical drug devel-
opment is not overly expensive, especially for the basic elements 
needed to pursue drug development and to bring the drug to clini-
cal testing. If the quality issues can be controlled (drug synthesis, 
stability testing), basic toxicity testing can be outsourced to any 
of many specialized companies. Obviously, academic laboratories 
should have all the required resources for pharmacodynamic testing 
and demonstration. Clinical trials can be done in the appropriate 
clinical investigation centers, and the academic hospitals of course 
have all the patients needed for the clinical trials, because this is 
usually where industry actually does them. Therefore, academia 
(including public hospitals and research centers) has all the required 
knowledge and resources needed to develop a drug and bring it to 
market. What may be most lacking at the premarket phase is financ-
ing, and finding this is not easy, especially at the later-phase clinical 
trials, which are usually multicenter and require heavy logistical 
resources. Recently developed networks and structures (E-CRIN, 
F-CRIN) aim to help these large multicenter studies. Increasing 
awareness by the public research-financing bodies of the need to be 
able to develop alternatives to industrial development, especially for 
certain types of drugs (drugs for rare diseases or new uses for old 
drugs), may also increase the involvement of academia in de novo 
drug development. Of course, public–private partnerships should 
continue, both through involvement of industry expertise during 
academia-initiated development and through the increasingly evi-
dent involvement of academia during later-phase clinical develop-
ment of major new drugs, if only to avoid unnecessary suspicions of 
industrial misconduct, much as is done in the postmarketing arena 
with the ENCEPP code of conduct.
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Summary: Transporters are membrane proteins, which medi-
ate the translocation of chemicals into and out of cells. The past 
10 years have seen an enormous increase in research concerning 
the role of membrane transporters in drug pharmacokinetics and 
response.1 In particular, influx and efflux transporters expressed 
on the plasma membranes of polarized cells in tissues important 
for pharmacokinetics have the potential to significantly affect 
drug response. Certain transporters have been shown to mediate 
clinically important drug interactions. For example, the immuno-
suppressive drug cyclosporine increases the systemic exposure to 
all statins, by ~5- to 20-fold, probably mainly by inhibiting their 
organic anion transporting polypeptide (OATP)-mediated hepatic 
uptake.3 Similarly, cyclosporine raises the systemic exposure to 
the OATP1B1 substrate antidiabetic repaglinide by 2.5-fold.2 
Furthermore, the P-glycoprotein efflux transporter-inhibiting anti-
mycotic itraconazole raises the systemic exposure to the antihy-
pertensive aliskiren on average 6.5-fold.4 These and other roles of 
OATPs, P-glycoprotein. and other membrane transporters in drug 
interactions will be discussed.
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Summary: Twenty years ago, there were almost no pharmacovigi-
lance (PV) activities in low-and middle-income countries (LMIC). 
Today, 144 countries are participating in the WHO Programme 
for International Drug Monitoring, and 102 of them belong to the 
LMIC category according to the World Bank classification. Many 
factors have contributed to the positive development. Among them 
are:
-  Creation of evidence of the general burden of drug-related harm 
in all populations
-  Concerns of the high prevalence of substandard and fake medicines 
in LMIC
-  Capacity building and competence development in PV, mainly 
driven by the WHO Programme
-  Public health programs realizing that drug-related harm may jeop-
ardize program success
-  Global health initiatives and donor organizations prepared to 
protect public health programs also by supporting pharmacovigi-
lance
Most of the national pharmacovigilance systems in LMIC still 
have inadequate capacity to adequately protect their populations 
from the risk of medicine and medicine use–related harm. There are 
many challenges that need to be addressed; for example:
-  The capacity of National Regulatory Authorities and collaboration 
and integration with vertical disease programs
-  Training of health workers, local industry, and the public about the 
need to record and report medicine-related harm
- Keeping of systematic patient records
-  Documentation of the burden of medicine-related harm in the local 
setting
In most LMICs, the first requisite for PV activities, the politi-
cal will, is in place. Further support for the young PV systems is 
needed to make them fully functional. The WHO Programme builds 
regional and global networks to support PV in LMIC particularly 
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by offering training opportunities, harmonized methods, tools, and 
data resources.
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Summary: In 1970, the World Health Organization (WHO) pub-
lished its well-known manifesto on clinical pharmacology, which for 
many years was the gold standard of the discipline.1 However, for 
the last 10 years or so it has been clearly in need of updating. This 
was finally achieved in 2012 after 3 to 4 years of work by the above-
named editors and a team of distinguished clinical pharmacologists 
from around the world. Their work was supported not only by the 
WHO but also by the Council for International Organizations of 
Medical Sciences (CIOMS) and the International Union of Basic and 
Clinical Pharmacology (IUPHAR). The document covers a number 
of different facets of the work of clinical pharmacologists but in par-
ticular highlights the role of clinical pharmacology in the delivery of 
health care.2 A recent questionnaire study in 31 European countries3 
has identified the weakness of clinical pharmacology in health care, 
particularly in its failure to provide clinical pharmacologic services 
that will promote the rational use of medicines (RUM).
The main chapter on “The Clinical Pharmacologist in Patient 
Care” covers a number of different ways in which the discipline 
can help deliver better patient care. The importance of the various 
modalities discussed will depend on the way in which health care is 
delivered in different countries. In a few countries, the clinical phar-
macologist (CP) will be directly involved in the care of both inpatients 
and outpatients. However, in the majority of countries, the CP will be 
more involved indirectly in patient care. In all countries, the CP will 
be closely involved in the critical evaluation of new and old therapies; 
in the work of Drug and Therapeutic committees, both national and 
local; and in services such as drug information, pharmacovigilance, 
and drug utilization studies. In addition, the CP in many countries is 
directly involved in therapeutic drug monitoring (TDM) and phar-
macogenetic services aiming to facilitate personalized medicine. The 
overall purpose of the manifesto is to strengthen the role of clinical 
pharmacology in achieving RUM, and this is the focus of the last 
chapter in the manifesto.
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Summary: The thalidomide disaster detected in 1961 initiated the 
first systematic international effort to address medicine safety issues 
at the global level. The Sixteenth World Health Assembly (1963) 
adopted a resolution (WHA 16.36) that reaffirmed the need for early 
action in regard to rapid dissemination of information on adverse 
reactions due to medicines and led to the WHO Programme for 
International Drug Monitoring. Under this program, systems have 
been developed in member states for the collection of individual 
case safety reports (ICSRs) and their evaluation. The reports are 
held in a central database, managed and maintained by the WHO 
Collaborating Centre for International Drug Monitoring, the Uppsala 
Monitoring Centre (UMC) in Sweden. The work of the UMC, with 
policy directives from WHO, serves the important function of con-
tributing to the work of national drug regulatory authorities and 
other relevant stakeholders, by improving the knowledge of safety 
profiles of medicines. As of June 2013, there are 144 countries partici-
pating in the program, with access to a WHO database containing > 8 
million ICSRs. This presentation will trace the growth of the program 
these last 40 years, address gaps in pharmacovigilance at national 
and international levels, determine trends and the most urgent PV 
priorities in defined settings, and identify the broad elements of a 
pharmacovigilance strategy that will promote quality health care 
and assure patient safety.
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Summary: Drug-induced liver injury (DILI) represents a significant 
cause of patient morbidity and mortality and is a major contributor 
to attrition in drug development. Prediction of clinical DILI remains 
difficult, particularly in cases characterized by marked interindividual 
variation. A lack of sensitivity, specificity, and an indirect mechanistic 
basis of currently used markers of hepatic injury remains a factor 
for the delayed identification of DILI. There is a need to discover, 
develop, and validate new biomarkers to better inform the medicinal 
chemist and the clinician. The ideal biomarker is 1 that is mechanism-
based, organ (cell) selective, and that can be used in both the clinic 
and laboratory models. Traditional biomarkers of DILI include leak-
age markers of cell death and markers of hepatic function. Preclinical 
DILI biomarker identification and validation have been focused on 
molecular biomarkers such as cytokeratin-18, high mobility group 
box-1 protein, and micoRNA-122, which are more informative with 
respect to chemical stress, adaptation, and mechanisms of cellular 
damage. Recent reports have shown that these hold translational 
application to inform both the sensitive identification of DILI and 
also its mechanistic basis in man. Furthermore, a number of these 
biomarkers provide enhanced prognostic information during clinical 
acetaminophen overdose. The integrated use of these and other mark-
ers will be discussed from a backdrop of imperfect current standards 
